Physician profile
Jorge N Martinez-Prieto
NPI 1447245469
$23,280.53
in general payments reported to CMS, 2019-2025
59 companies · $2,615 in 2025
The $2,615 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,904 · 2020: $3,066 · 2021: $3,888 · 2022: $3,402 · 2023: $4,108 · 2024: $3,298 · 2025: $2,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,970 · Education: $50.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,970.40 |
| Education | $50.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $2,723.22 | 2019-2025 | Mavenclad |
| Ucb, INC. | $2,037.28 | 2019-2024 | Briviact, Rystiggo, Nayzilam |
| Novartis Pharmaceuticals Corporation | $1,724.79 | 2019-2025 | |
| Celgene Corporation | $1,533.60 | 2022-2025 | Zeposia |
| Tg Therapeutics, INC. | $1,411.83 | 2023-2025 | |
| Genentech USA, INC. | $1,263.95 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $1,175.63 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $1,129.51 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $975.39 | 2020-2025 | Ingrezza, Ongentys |
| Amgen INC. | $854.36 | 2019-2023 | Enbrel |
| Acadia Pharmaceuticals INC | $771.84 | 2019-2023 | Nuplazid |
| Mdd US Operations, LLC | $496.59 | 2019-2024 | Gocovri, Gocovri |
| Sunovion Pharmaceuticals INC. | $480.98 | 2019-2022 | |
| Sk Life Science, INC. | $479.23 | 2020-2025 | |
| Pfizer INC. | $472.08 | 2023-2025 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $467.32 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Kyowa Kirin, INC. | $454.93 | 2019-2023 | Nourianz |
| Eisai INC. | $356.68 | 2020-2023 | |
| Lilly USA, LLC | $349.16 | 2019-2024 | Emgality |
| Biohaven Pharmaceuticals, INC. | $330.97 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $325.51 | 2019-2024 | Ultomiris |
| Argenx US, INC. | $286.77 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Catalyst Pharmaceuticals, INC. | $264.67 | 2021-2025 | Fycompa |
| Genzyme Corporation | $245.85 | 2019-2022 | |
| Biogen, INC. | $232.13 | 2020-2025 | Leqembi, Tysabri, Vumerity |
| Neurelis, INC. | $215.50 | 2020-2024 | Valtoco |
| Ge Healthcare | $215.20 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $178.31 | 2022 | |
| Supernus Pharmaceuticals, INC. | $177.83 | 2019-2022 | |
| Octapharma USA, INC. | $176.95 | 2022-2025 | Panzyga |
| Janssen Pharmaceuticals, INC | $138.53 | 2021 | |
| Corium, LLC | $127.64 | 2022-2023 | Adlarity |
| Allergan, INC. | $117.44 | 2020 | |
| Lundbeck LLC | $84.81 | 2021-2024 | Rexulti |
| Amneal Pharmaceuticals LLC | $79.56 | 2020-2025 | Rytary, Crexont |
| Adamas Pharmaceuticals, INC. | $79.23 | 2020-2021 | |
| Otter Pharmaceuticals, LLC | $72.97 | 2025 | Sympazan |
| Takeda Pharmaceuticals U.S.A., INC. | $60.99 | 2022-2023 | Gammagard |
| Abbott Laboratories | $58.16 | 2021-2025 | Proclaim |
| Avanir Pharmaceuticals, INC. | $57.76 | 2019 | |
| Sumitomo Pharma America, INC. | $54.63 | 2023 | Aptiom |
| Avion Pharmaceuticals | $52.50 | 2022-2023 | Dhivy |
| Impel Pharmaceuticals INC. | $47.92 | 2023 | Trudhesa |
| Greenwich Biosciences, INC. | $42.07 | 2019-2020 | |
| Medtronic, INC. | $40.36 | 2024-2025 | Percept Pc Brainsense |
| Upsher-Smith Laboratories LLC | $39.35 | 2020 | |
| Csl Behring | $39.21 | 2019-2020 | |
| Acorda Therapeutics, INC | $37.30 | 2022-2024 | Inbrija, Ampyra |
| Ani Pharmaceuticals, INC. | $34.66 | 2025 | Purified Cortrophin Gel |
| Bausch Health US, LLC | $34.18 | 2019 | |
| Aquestive Therapeutics, INC. | $28.17 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $24.88 | 2020-2021 | |
| Grt US Holding, INC. | $22.45 | 2022 | |
| Averitas Pharma INC. | $21.17 | 2023 | Qutenza |
| Promius Pharma LLC | $18.84 | 2019 | |
| Sanofi Pasteur INC. | $17.11 | 2022 | |
| Currax Pharmaceuticals LLC | $13.99 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $13.51 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Martinez-Prieto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.